On September 15, REVVITY INC rose 6.11% in regular trading, trading at $136.375/share, with turnover of approximately $51.96 million.

On the news front, the company recently announced the acquisition of France-based biotech firm Human Cell Design (HCD), which specializes in developing human cell models for metabolic diseases such as diabetes and obesity. Following the deal's completion, HCD's human pancreatic beta-cell models will be integrated into REVVITY INC's Life Sciences portfolio, enhancing its drug discovery and screening capabilities for GLP-1 and other metabolic disease therapies while expanding applications in regenerative medicine and cell therapy. The transaction is expected to close in the fourth quarter, pending regulatory approval; financial terms were not disclosed.

Meanwhile, analyst sentiment has been broadly supportive. UBS recently upgraded its price target to $140 while shifting to Neutral, and Baird raised its target to $144 maintaining an Outperform rating. The company also reported a strong Q2, with adjusted EPS of $1.41 beating estimates by over 15%, and raised full-year guidance to $5.30–$5.40 adjusted EPS versus consensus of $5.24.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)